-
Posted by
Two Blokes Jun 29 -
Filed in
Stock
-
5 views
With the notable exceptions of Novo Nordisk A/S NYSE: NVO and Eli Lilly & Co. NYSE: LLY, biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech stocks struggled to raise capital in a higher-for-longer interest rate environment.
